A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature

Francesca Bacchiarri\textsuperscript{1} \| Alessandro Gozzetti\textsuperscript{1} \| Nicola Mondanelli\textsuperscript{2} \| Stefano Lazzi\textsuperscript{3} \| Monica Bocchia\textsuperscript{1}

\textsuperscript{1}Department of Hematology, University of Siena, Siena, Italy
\textsuperscript{2}Department of Orthopedic Surgery, University of Siena, Siena, Italy
\textsuperscript{3}Anatomic Pathology Department, University of Siena, Siena, Italy

Abstract
Skeletal involvement in CLL is very rare. We present a case of ileum bone lesion during in a patient receiving 5th line of therapy. Despite radiotherapy and salvage therapies, subsequent bone lesions led to a fatal outcome. Further studies on the mechanism by which bone disease develops are currently needed.

KEYWORDS
chronic lymphocytic leukemia, hypercalcemia, osteolysis

1 | INTRODUCTION

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, with a predominance in the elderly and an increasing incidence with age.\textsuperscript{1} Characterized by heterogeneous clinical course, CLL has predominantly a B-cell origin, with a clonal expansion of mature CD5\textsuperscript{+} CD23\textsuperscript{+} B-lymphocytes that accumulate in the bone marrow and infiltrate lymphoid tissues such as the spleen and lymph nodes.\textsuperscript{2}

Treatment has changed over the last 30 years from chemotherapy, to chemo-immunotherapy and lately to novel agents (i.e., BTK inhibitors and BCL-2 inhibitor).\textsuperscript{3–5}

Rarely, patients can experience a skeletal progression, variously associated with hypercalcemia, as reported by some authors. Herein, we present a case of skeletal progression in a 74-year-old male patient with a 10-year history of CLL with del17p and unmutated IGHV, receiving venetoclax as 5th line of therapy.

2 | CASE PRESENTATION

The patient was diagnosed with CLL in 2009: He presented with a performance status (PS) 1, mild lymphocytosis (WBC 9 \times 10^9/L, lymphocytes count 5300 \times 10^9/L, Hb 13 g/dL, and platelets 145 \times 10^9/L), diffuse lymphadenopathies (laterocervical and axillary lymph nodes of maximum diameter 2 cm), splenomegaly, and left testicular swelling. Bone marrow aspiration was positive for CLL (CD5\textsuperscript{+} CD19\textsuperscript{+} CD23\textsuperscript{+} CD20\textsuperscript{+} CD38\textsuperscript{−}); fluorescence in situ hybridization (FISH) analysis showed chromosome 17p deletion (20% of nucleated cells) and unmutated IGHV. The patient underwent left orchiectomy that confirmed CLL diagnosis. After 4 cycles of chemotherapy with fludarabine and alemtuzumab, he obtained a partial remission of the disease. Patient underwent maintenance therapy with rituximab until October 2012. In December 2012, due to a disease relapse with anemia, splenomegaly, and lymphadenopathy, 2nd line therapy with rituximab...
and bendamustine was started. After 4 cycles, patient was in stable disease; therefore, a therapy with alemtuzumab and cyclophosphamide was administered from April to September 2013.

Patient remained asymptomatic until June 2014, when massive splenomegaly, anemia, and lymphocytosis were again found. A therapy with BTK inhibitor (ibrutinib) was started. For a episode of autoimmune hemolytic anemia, he required corticosteroids therapy. Patient obtained a partial remission and continued ibrutinib until March 2018, when a therapy with BCL-2 inhibitor (venetoclax) was started for massive lymph nodes enlargement. Patient had a complete remission until August 2019 when he was admitted to the Emergency Unit for lower limbs pain complained for about 2 months. Radiographs and CT scan demonstrated a left iliac bone pathological fracture due to a bone lesion that also affected the soft intrapelvic tissues, occupying and replacing the iliopsoas muscle (maximum diameter of the lesion 10 cm), as shown in Figure 1. A core needle bone biopsy performed under radiographic guidance confirmed CLL diagnosis (Figure 2). Physical examination revealed no lymphadenopathy nor organomegaly (PS = 2). Laboratory findings showed no lymphocytosis with WBC $2.3 \times 10^9$/L (lymphocyte count 15%), Hb 11.4 g/dL, and platelets $137 \times 10^9$/L. Serum total proteins were low (5.6 g/dL), without monoclonal component. Uric acid (4.3 mg/dL) and serum alkaline phosphatase (125 U/L) were normal, with elevated calcium (14.6 mg/dL), β2-microglobulin (4.9 mg/L), and serum lactate dehydrogenase (250 U/L). PTH analysis was not performed. Bone marrow aspiration showed CLL infiltrate.

The fracture was treated conservatively, and radiotherapy was administered at the dose of 30 Gy, but other lytic lesions of the contralateral acetabulum, 3rd left rib, and left clavicle leading to pathological fractures occurred. The patient was subsequently treated with 1 cycle of intravenous rituximab, continuing with venetoclax plus zoledronic acid as prophylaxis. Despite the radiotherapy and intensification of immunotherapy, patient developed multiple cranial lytic lesions, involving epidural and dural tissue and left occipitotemporal leptomeningeal infiltration, and he died 3 months later.

3 | DISCUSSION

CLL is the commonest form of leukemia, presenting often with asymptomatic peripheral lymphocytosis. The clinical course can be very heterogenous with lymphadenopathy, increased incidence of infection, autoimmune phenomena (e.g., hemolytic anemia, thrombocytopenia), and B symptoms (fever, unintentional weight loss, night sweats, and severe fatigue). Active treatment is required with advanced disease stage, evidence of disease progression (e.g., cytopenias, lymphadenopathy of 10 cm, and/or splenomegaly), and/or in the presence of constitutional B symptoms. In case of relapse, the presentation can be identical or characterized by transformation to high-grade lymphoma (Richter’s syndrome). Macroscopic skeletal involvement is extremely rare, being more frequent in other lymphoproliferative disease and some acute leukemias. Altered bone metabolism, resorption, and
demineralization can lead to an increased risk of spine and pelvic fractures in untreated patients.\textsuperscript{7-9} Some cases in literature have already described the presence of lytic lesions in patients affected by CLL, and one of them was previously described by our group.\textsuperscript{10} In 11 on 22 cases of the literature, patients had the axial skeleton or proximal long bones involved,\textsuperscript{10-21} and in rare cases, fractures were localized to the skull or facial bones.\textsuperscript{17,22,23} Multiple fractures were reported in 8 cases.\textsuperscript{24-31} Like this one, other cases in the literature described pathological fracture due to CLL involving the spine and vertebral compression fractures.\textsuperscript{16,19,29,30} Of note, in 13 reports symptomatic osteolysis was the first presentation of a CLL. The cases reported in the literature are summarized in Table 1. Interestingly, pathological fracture can be also the first presentation of a newly diagnosed CLL. Hypercalcemia is a frequent finding with osteolysis and can be related to Richter’s transformation, or co-occurring multiple myeloma. The pathogenesis is not well understood and can be related to primary hyperparathyroidism,\textsuperscript{32} increased serum immunoreactive parathormone (iPTH), or osteoclast-activating factor (OAF).\textsuperscript{33}

In a recent study,\textsuperscript{34} bone erosion was particularly evident in long bone shafts, progressively increased from Binet stage A to Binet stage C, and it was directly related to the number of RANKL + cells present in the circulating blood. Also, after denosumab administration to CLL cells in vitro the expression of RANK decreased and also cell proliferation, this could partially be explained by the interaction between CLL lymphocytes and stromal cells.

4 | CONCLUSIONS

Our patient had a 10-year history of CLL, with several relapses, and eventually developed multiple osteolytic lesions associated with hypercalcemia. PTH analysis was not performed; however, in an end-stage disease characterized by several skeletal lytic lesions, hypercalcemia can be a common finding.

The pathogenesis of bone involvement in CLL is not completely understood, and it is associated with Richter disease in the majority of cases. Of note, in 13 cases patients developed bone metastases/presented symptomatic bone lesions as first presentation of a CLL.
**TABLE 1** Overview of previously reported cases of CLL compromised by osseous bone lesions and/or hypercalcemia

| Ref.          | Age/Sex | Stage/new diagnosis | WBC (10^9/L) | Lym (10^9/L) | Hb (g/dL) | Plt (10^9/L) | M protein | Bone lesions | Hypercalcemia | Treatment                      | Prognosis |
|---------------|---------|---------------------|--------------|--------------|-----------|-------------|-----------|--------------|---------------|-------------------------------|-----------|
| Laugener (1979) | 69/M    | IIIC/Y              | 35.2/99%     | 9.3          | 11.4      | 9.3          | −         |              |              | CVP                           | 7 M, dead |
| McMillian (1980) | 73/F    | NA/Y                | 28.7/78%     | 12.9         | 22        | 11.2        | +         |              |              | Chlorambucil, Prednisone       | 3 W Alive |
| Redmond (1983)  | 70/M    | NA/Y                | 66.3/90%     | 19.2/98%     | 62.9      | 82          | −         |              |              | Prednisone                    | 1.5 y dead|
| Rossi (1987)    | 70/F    | Rai IIY             | 80.8/98%     | 8.6          | 76        | 12          | +         |              |              | Chlorambucil                  | Alive     |
| Rossi (1987)    | 70/M    | NA/Y                | 68.3/90%     | 12.8         | 76        | 12          | +         |              |              | Prednisone                    | 10 M Dead |
| Redmon (1983)   | 70/M    | NA/Y                | 66.3/90%     | 19.2/98%     | 62.9      | 82          | −         |              |              | Chlorambucil                  | 1 M, dead |
| Abboud (1985)   | 74/M    | NA/Y                | 95/80%       | 9.1          | 12        | 8.5         | +         |              |              | Prednisone                    | 3 M Dead  |
| Rossi (1987)    | 74/M    | NA/Y                | 95/80%       | 12.2         | 76        | 12          | +         |              |              | Prednisone                    | 1 M, dead |
| Rossi (1987)    | 72/F    | NA/Y                | 80.8/98%     | 8.6          | 76        | 12          | +         |              |              | Chlorambucil                  | Alive     |
| Littlewood (1990) | 70/M  | Rai IIY             | 14.6/81%     | 9.1          | 12        | 8.5         | +         |              |              | Prednisone                    | 1 M, dead |
| Redmon (1983)   | 72/M    | NA/Y                | 68.3/90%     | 19.2/98%     | 62.9      | 82          | −         |              |              | Prednisone                    | 1 M, dead |
| Fabry (1997)    | 72/M    | NA/Y                | 19.2/98%     | 9.1          | 12        | 8.5         | +         |              |              | Prednisone                    | Alive     |
| Wright (1997)   | 72/M    | NA/Y                | 68.3/90%     | 19.2/98%     | 62.9      | 82          | −         |              |              | Prednisone                    | Alive     |
| Yau (2003)      | 66/F    | NA/Y                | 16.2/0.6     | 14.9         | 177       | 11.2        | +         |              |              | Prednisone                    | Alive     |
| Narayanan (2005)| 83/M    | NA/Y                | 10.8/0.4/L   | 10.1         | 119       | 12.2        | +         |              |              | Prednisone                    | Alive     |
| Fabbri (2004)   | 72/F    | Binet C/N           | 43.5/78%     | 10.8         | 196       | 119         | +         |              |              | Prednisone                    | Alive     |
| Man (2011)      | 81/M    | NA/Y                | 117/98%      | 13.9         | 119       | 12.2        | +         |              |              | Prednisone                    | Alive     |
| Mian (2011)     | 81/M    | NA/Y                | 3.52/57%     | 12.7         | 6.2       | 119         | +         |              |              | Prednisone                    | Alive     |
| Man (2011)      | 81/M    | NA/Y                | 3.52/57%     | 12.7         | 6.2       | 119         | +         |              |              | Prednisone                    | Alive     |
| Hua (2018)      | 65/F    | Rai IIY             | 10.9/83%     | 9.1          | 18.9      | 11.4        | +         |              |              | Prednisone                    | 2 M, dead |
| Katz (2018)     | 76/F    | NA/Y                | 10.9/83%     | 9.1          | 18.9      | 11.4        | +         |              |              | Prednisone                    | Alive     |
| Present case    | 69/M    | IVC                 | 10.9/83%     | 9.1          | 18.9      | 11.4        | +         |              |              | Venetoclax + R                 | 2 M, dead |

Note: Adapted from Hua et al.15

Abbreviations: BR, bendamustine, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete remission; CVP, cyclophosphamide, vincristine, prednisone; Chlor, chlorambucil, FC, fludarabine, cyclophosphamide, FCR, fludarabine, cyclophosphamide, rituximab; FR, fludarabine, rituximab; L, lymphopenia; N, normal; NA, not available; PDN, prednisone; PM, platelet; RT, radiotherapy; VAD, vincristine, adriamycin, dexamethasone; WBC, white blood cell.
Bone erosions in patient affected by CLL can be related to an increased expression of RANK or locally released osteoclast stimulating factors.

This overview suggests that bone lesion is not rare events in CLL and further investigation is required to clarify the underlying mechanism and to find suitable therapies for this group of patients, which often presents a high morbidity and mortality.

ACKNOWLEDGMENT
None.

CONFLICT OF INTEREST
The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

AUTHOR CONTRIBUTIONS
FB wrote the manuscript, AG followed the patient, NM performed patient’s bone biopsy, SL analyzed bone biopsy, and MB designed the study. All authors have contributed to, read, and approved the manuscript and this submission.

CONSENT
Written informed consent was obtained from the relatives of deceased patient to publish this report in accordance with the journal’s patient consent policy.

ORCID
Francesca Bacchiari https://orcid.org/0000-0001-6186-3895
Alessandro Gozzetti https://orcid.org/0000-0003-0769-6891
Nicola Mondanelli https://orcid.org/0000-0002-0684-4197
Stefano Lazzi https://orcid.org/0000-0002-2218-3771
Monica Bocchia https://orcid.org/0000-0003-3538-3913

REFERENCES
1. Baumann T, Delgado J, Santacruz R, et al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica. 2014;99(10):1599-1604.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
3. Zinzani PL, Luria F, Rondelli D, et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Haematol. 1993;51(2):93-97.
4. Laurenti L, Innocenti I, Autore F, et al. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: a retrospective analysis of real-life practice in Italian hematology departments. Leuk Res. 2015;39(10):1066-1070.
5. Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, Bocchia M. Bruton kinase inhibitors in chronic lymphocytic leukemia. Anticancer Agents Med Chem. 2017;17(8):1040-1045.
6. Mauro FR, Galieni P, Tedeschi A, et al. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. Am J Hematol. 2017;92(6):529-535.
7. Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol. 2011;152:441-451.
8. Olszewski AJ, Gutman R, Eaton CB. Increased fracture rate in patients with untreated chronic lymphocytic leukemia (CLL): a population-based analysis. Blood. 2015;126:878.
9. Olszewski AJ, Gutman R, Eaton CB. Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis. Haematologica. 2016;101:e488-e491.
10. Fabbri A, Gozzetti A, Marotta G, et al. An unusual presentation of chronic B-cell lymphocytic Leukaemia. Br J Haematol. 2004;124(2):129.
11. Abboud SL, Gordeuk V, Schacter LP, Crum ED, Spitzer TR. Well-differentiated lymphocytic lymphoma with peripheral blood involvement, osteolytic bone lesions, and hypercalcemia. A case report and review of the literature. Cancer. 1985;56(10):2508-2511.
12. Hatoum G, Meshkin C, Alkhunaizi S, Levene R, Formoso-Onorio J. The Risk of misdiagnosing the primary site responsible for bone metastases in patients with chronic lymphocytic leukemia and a second primary carcinoma. World J Oncol. 2015;6(2):332-334.
13. Katz H, Sagun S, Griswold D, Alishareedi M. Solitary lytic bone metastasis: a rare presentation of small lymphocytic leukemia. Case Rep Hematol. 2018;2018:6154709.
14. Het ZM, Gomez C, Ali A, Nair S, Karim M. Multiple faces of chronic lymphocytic leukemia: a patient with renal, cardiac and skeletal complications. Case Rep Nephrol. 2019;2019(2019):5390235.
15. Hua J, Ide S, Ohara S, et al. Hypercalcemia and osteolytic bone lesions as the major symptoms in a chronic lymphocytic leukaemia/small lymphocytic lymphoma patient: a rare case. J Clin Exp Hematopathol. 2018;58(4):171-174.
16. Langenberg JCM, Bosman WM, Bremer J, Ritchie ED. Pathological fractures in a patient with chronic lymphatic leukaemia without disease progression. BMJ Case Rep. 2015;2015:bcr2014208118.
17. Littlewood TJ, Lydon APM, Barton CJ. Hypercalcemia and osteolytic lesions associated with chronic lymphatic leukaemia (CLL). J Clin Path. 1990;43(10):877.
18. Narayan H, Bandyopadhyay D, Schmidt K, et al. Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy. Clin Lab Haematol. 2005;27:405-408.
19. Redmond J, Stites DP, Beckstead JH, George CB, Casavant CH, Gandara DR. Chronic lymphocytic leukaemia with osteolytic bone lesions, hypercalcemia, and monoclonal protein. Am J Clin Path. 1983;79:616-620.
20. Yau V, Christakis M, Ismiil N, et al. Chronic lymphocytic leukemia resembling metastatic bone disease-unusual manifestation. *J Pain Symptom Manage*. 2003;26(6):1074-1076.

21. Soni P, Aggarwal N, Rai A, et al. Chronic lymphocytic leukemia: a rare cause of pathological fracture of the femur. *J Investig Med High Impact Case Rep*. 2017;5(4):2324709617735135.

22. Dunphy CH, Oza YV, Skelly ME. Previously undescribed form of B-cell chronic lymphoid leukemia with IgA expression/secretion and lytic bone lesions. *Am J Hematol*. 1997;55(4):208-211.

23. Wright GW, Wiesenfeld D, Seymour JF. Bilateral fracture of the mandible in chronic lymphocytic leukaemia. Case report. *Aust Dent J*. 1997;42:20-24.

24. Ailawadhi S, Baddoura FK, Haumesser JC, et al. Hypercalcemia and osteolytic bone lesions in B-cell chronic lymphocytic leukemia: a case report. *Clin Leukemia*. 2006;1(1):57-60.

25. Alanoglu G, Dagdas S, Aki Z. Hypercalcemia and multiple pathological fractures in chronic lymphocytic leukaemia: a case report. *Turk J Haematol*. 2003;20(3):167-170.

26. Greenfield HM, Hunt R, Lee LK, Jowitt SN. B-cell chronic lymphocytic leukaemia with extensive lytic lesions. *Eur J Haematol*. 2006;76:356-357.

27. Mian M, Cerú S, Billio A, Rosanelli C, Cortelazzo S. Osteolytic bone lesions as a rare sign of progression of chronic lymphocytic leukemia without evidence of Richter syndrome. *Leukemia Lymphoma*. 2012;53(5):993-995.

28. Rossi J-F, Bataille R, Chappard D, Alexandre C, Janbon C. B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Study of nine cases. *Am J Med*. 1987;83(1):10-16.

29. McMillan P, Mundy G, Mayer P. Hypercalcemia and osteolytic bone lesions in chronic lymphocytic leukaemia. *Br Med J*. 1980;280:1107.

30. Van de Casteele M, Verhoef GEG, Demuynck H, Zacheé P, Boogaerts MA. Hypercalcemia, monoclonal protein, and osteolytic bone lesions in chronic lymphocytic leukemia. *Ann Hematol*. 1994;69:79-80.

31. Fain O, Selmi A, Dosquet C, et al. Hypercalcemia in B-cell chronic lymphocytic leukemia. *Br J Haematol*. 1994;87:856-858.

32. Laugen RH, Carey RM, Wills RW, Hess CE. Hypercalcemia associated with chronic lymphocytic leukemia. *Arch Intern Med*. 1979;139:1307.

33. Mundy GR, Raisz LG, Cooper R, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. *N Engl J Med*. 1974;290:867.

34. Marini C, Bruno S, Fiz F, et al. Functional activation of osteoclast commitment in chronic lymphocytic leukaemia: a possible role for RANK/RANKL pathway. *Scientific Reports*. 2017;7(1):14159.

How to cite this article: Bacchiarri F, Gozzetti A, Mondanelli N, Lazzi S, Bocchia M. A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature. *Clin Case Rep*. 2022;10:e05379. doi:10.1002/ccr3.5379